Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Production. Per the activity note to the FY2024 annual report, the company produces pharmaceutical preparations and medicines.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 7,068 | 6,619 | 10,847 | 12,858 | 12,412 | 9,686 | 10,150 | +6.2% | |
| Total COGS | 5,301 | 1 | 7,675 | 7,942 | 6,317 | 4,651 | 4,625 | -2.2% |
| Gross Profit | 1,767 | 6,618 | 3,173 | 4,915 | 6,095 | 5,035 | 5,525 | +20.9% |
| Gross Margin | 25.0% | 100.0% | 29.3% | 38.2% | 49.1% | 52.0% | 54.4% | |
| 1,590 | 7,146 | 2,940 | 3,892 | 5,707 | 5,462 | 6,373 | +26.0% | |
| EBITDA | 178 | 528 | 233 | 1,023 | 388 | 427 | 847 | nmf |
| EBITDA Margin | 2.5% | 8.0% | 2.1% | 8.0% | 3.1% | 4.4% | 8.3% | |
| Total D&A | 520 | 549 | 281 | 292 | 362 | 491 | 313 | -8.1% |
| EBIT / Operating Income | 343 | 1,077 | 48 | 731 | 26 | 918 | 1,161 | +22.5% |
| 137 | 419 | 112 | 46 | 186 | 192 | 115 | -2.9% | |
| Profit Before Tax | 480 | 1,496 | 64 | 684 | 160 | 1,110 | 1,276 | +17.7% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 732 | 947 | 214 | 938 | 160 | 1,110 | 1,276 | +9.7% |
| Net Margin | 10.4% | 14.3% | 2.0% | 7.3% | 1.3% | 11.5% | 12.6% | |
| Other Comprehensive Income | 0 | 0 | 2,385 | 2,385 | 2,385 | 2,385 | 2,385 | +0.0% |
| Total Comprehensive Income | 732 | 947 | 2,599 | 3,323 | 2,225 | 1,275 | 1,109 | nmf |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.